| Top down characterization of larger proteins (45 kDa) by electron capture dissociation mass spectrometry Y Ge, BG Lawhorn, M ElNaggar, E Strauss, JH Park, TP Begley, ... Journal of the American Chemical Society 124 (4), 672-678, 2002 | 473 | 2002 |
| Biosynthesis of the thiamin pyrimidine: the reconstitution of a remarkable rearrangement reaction BG Lawhorn, RA Mehl, TP Begley Organic & biomolecular chemistry 2 (17), 2538-2546, 2004 | 95 | 2004 |
| Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart RJ Vagnozzi, GJ Gatto Jr, LS Kallander, NE Hoffman, K Mallilankaraman, ... Science translational medicine 5 (207), 207ra141-207ra141, 2013 | 73 | 2013 |
| Total synthesis and evaluation of cytostatin, its C10− C11 diastereomers, and additional key analogues: impact on PP2A inhibition BG Lawhorn, SB Boga, SE Wolkenberg, DA Colby, CM Gauss, ... Journal of the American Chemical Society 128 (51), 16720-16732, 2006 | 70 | 2006 |
| A genetic screen for the identification of thiamin metabolic genes BG Lawhorn, SY Gerdes, TP Begley Journal of Biological chemistry 279 (42), 43555-43559, 2004 | 64 | 2004 |
| Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (β12–β13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight … MR Swingle, L Amable, BG Lawhorn, SB Buck, CP Burke, P Ratti, ... Journal of Pharmacology and Experimental Therapeutics 331 (1), 45-53, 2009 | 62 | 2009 |
| Recent advances in TRPV4 agonists and antagonists BG Lawhorn, EJ Brnardic, DJ Behm Bioorganic & Medicinal Chemistry Letters 30 (8), 127022, 2020 | 47 | 2020 |
| Identification of purines and 7-deazapurines as potent and selective type I inhibitors of troponin I-interacting kinase (TNNI3K) BG Lawhorn, J Philp, Y Zhao, C Louer, M Hammond, M Cheung, H Fries, ... Journal of medicinal chemistry 58 (18), 7431-7448, 2015 | 45 | 2015 |
| Detection of four oxidation sites in viral prolyl‐4‐hydroxylase by top‐down mass spectrometry Y Ge, BG Lawhorn, M ElNaggar, SK Sze, TP Begley, FW McLafferty Protein Science 12 (10), 2320-2326, 2003 | 44 | 2003 |
| Discovery of GSK2798745: a clinical candidate for inhibition of transient receptor potential vanilloid 4 (TRPV4) CA Brooks, LS Barton, DJ Behm, HS Eidam, RM Fox, M Hammond, ... ACS medicinal chemistry letters 10 (8), 1228-1233, 2019 | 41 | 2019 |
| TRPV4 antagonists: A patent review (2015–2020) BG Lawhorn, EJ Brnardic, DJ Behm Expert Opinion on Therapeutic Patents 31 (9), 773-784, 2021 | 30 | 2021 |
| Design and optimization of sulfone pyrrolidine sulfonamide antagonists of transient receptor potential vanilloid-4 with in vivo activity in a pulmonary edema model JE Pero, JM Matthews, DJ Behm, EJ Brnardic, C Brooks, BW Budzik, ... Journal of Medicinal Chemistry 61 (24), 11209-11220, 2018 | 27 | 2018 |
| Substituent effects on drug–receptor H-bond interactions: correlations useful for the design of kinase inhibitors BG Lawhorn, J Philp, AP Graves, DA Holt, GJ Gatto Jr, LS Kallander Journal of Medicinal Chemistry 59 (23), 10629-10641, 2016 | 25 | 2016 |
| Discovery of pyrrolidine sulfonamides as selective and orally bioavailable antagonists of transient receptor potential vanilloid-4 (TRPV4) EJ Brnardic, G Ye, C Brooks, C Donatelli, L Barton, J McAtee, ... Journal of Medicinal Chemistry 61 (21), 9738-9755, 2018 | 23 | 2018 |
| 4, 6-Diaminopyrimidines as highly preferred troponin I-interacting kinase (TNNI3K) inhibitors J Philp, BG Lawhorn, AP Graves, L Shewchuk, KL Rivera, LJ Jolivette, ... Journal of medicinal chemistry 61 (7), 3076-3088, 2018 | 23 | 2018 |
| Discovery of GSK3527497: A candidate for the inhibition of transient receptor potential vanilloid-4 (TRPV4) CA Brooks, LS Barton, DJ Behm, EJ Brnardic, MH Costell, DA Holt, ... Journal of Medicinal Chemistry 62 (20), 9270-9280, 2019 | 22 | 2019 |
| Reverse hydroxamate inhibitors of bone morphogenetic protein 1 LS Kallander, D Washburn, MA Hilfiker, HS Eidam, BG Lawhorn, ... ACS Medicinal Chemistry Letters 9 (7), 736-740, 2018 | 21 | 2018 |
| GSK114: A selective inhibitor for elucidating the biological role of TNNI3K BG Lawhorn, J Philp, AP Graves, L Shewchuk, DA Holt, GJ Gatto Jr, ... Bioorganic & Medicinal Chemistry Letters 26 (14), 3355-3358, 2016 | 13 | 2016 |
| Identification, synthesis, and characterization of a major circulating human metabolite of TRPV4 antagonist GSK2798745 JE Pero, JJ McAtee, DJ Behm, J Briand, G Graczyk-Millbrandt, K Erhard, ... ACS Medicinal Chemistry Letters 12 (9), 1498-1502, 2021 | 9 | 2021 |
| Design and optimization of an acyclic amine series of TRPV4 antagonists by electronic modulation of hydrogen bond interactions JR Patterson, LR Terrell, CA Donatelli, DA Holt, LJ Jolivette, RA Rivero, ... Journal of Medicinal Chemistry 63 (23), 14867-14884, 2020 | 9 | 2020 |
